two
decad
ago
success
transfect
antigen
present
cell
apc
vivo
demonstr
result
induct
primari
adapt
immun
respons
due
good
biocompat
plasmid
dna
costeffici
product
long
shelf
life
mani
research
aim
develop
dna
vaccinebas
immunotherapeut
strategi
treatment
infect
cancer
also
autoimmun
diseas
allergi
review
aim
summar
current
knowledg
cours
action
dna
vaccin
factor
respons
poor
immunogen
human
far
import
optim
step
improv
dna
transfect
effici
compris
introduct
dnacomplex
nanocarri
aim
prevent
extracellular
dna
degrad
enabl
apc
target
enhanc
endolysosom
escap
dna
attach
virusderiv
nuclear
local
sequenc
facilit
nuclear
entri
dna
improv
dna
vaccin
design
includ
use
apcspecif
promotor
transcript
target
arrang
multipl
antigen
sequenc
codeliveri
molecular
adjuv
prevent
toler
induct
strategi
circumv
potenti
inhibitori
effect
vector
backbon
success
clinic
use
dna
vaccin
may
requir
combin
employ
paramet
combin
treatment
addit
drug
compar
convent
proteinpeptidebas
vaccin
intend
induc
antigenspecif
adapt
immun
respons
dna
vaccin
stabl
costeffici
easi
manufactur
safe
handl
dna
vaccin
investig
variou
applic
includ
therapi
cancer
allergi
autoimmun
infecti
diseas
us
moment
clinic
trial
focu
dna
vaccin
regist
target
especi
viral
infect
cancer
bacteri
infect
autoimmun
diseas
less
topic
high
number
dnavaccin
test
clinic
trial
emphas
import
role
futur
medic
approach
review
aim
summar
current
achiev
ongo
develop
design
optim
dna
vaccin
deliveri
method
classic
way
vaccin
deliveri
intramuscular
intraderm
subcutan
inject
address
primarili
myocyt
keratinocyt
respect
also
antigen
present
cell
apc
resid
near
inject
side
figur
case
dna
vaccin
intern
dna
need
transloc
nucleu
transcript
follow
translat
cytoplasm
dna
vaccin
intend
induc
adapt
immun
respons
need
encod
antigen
adjuv
accord
plasmid
dna
appli
either
system
topic
eg
intramuscular
inject
transfect
keratinocyt
myocyt
express
transgen
releas
deriv
peptideprotein
via
exosom
apoptot
bodi
materi
endocytos
immatur
dendrit
cell
idc
subsequ
present
antigen
preferenti
via
major
histocompat
class
mhcii
cell
drain
lymph
node
direct
transfect
apc
includ
idc
result
endogen
transgen
express
henc
parallel
present
via
mhci
mhcii
yield
cell
respons
parallel
besid
cellular
immun
respons
humor
immun
respons
induc
b
cell
receptor
recogn
protein
antigen
acquir
help
preactiv
antigenspecif
cell
apc
transfect
directli
dna
vaccin
case
encod
antigen
express
process
antigenderiv
peptid
load
parallel
onto
mhci
mhcii
molecul
case
concomit
activ
antigenpres
apc
migrat
drain
lymph
node
prime
helper
cell
case
cutan
applic
transfect
keratinocyt
may
gener
antigen
releas
exosom
apoptot
bodi
intern
apc
gener
antigen
exogen
origin
load
rather
exclus
mhcii
result
activ
helper
cell
turn
contribut
b
cell
prime
yield
humor
immun
respons
requir
full
activ
cell
far
subpopul
dendrit
cell
dc
socal
cross
prime
potenti
abl
load
mhci
intern
antigen
intramuscular
applic
transfect
myocyt
may
undergo
apoptosi
apoptot
bodi
engulf
apc
exogen
antigen
crosspres
mhci
result
cell
respons
earli
studi
dna
vaccin
demonstr
prime
cytotox
lymphocyt
ctl
mostli
depend
bone
marrowderiv
dc
rather
induc
tissu
specif
cell
strictli
depend
cell
help
dna
vaccin
intend
induc
adapt
immun
respons
need
encod
antigen
adjuv
accord
plasmid
dna
appli
either
system
topic
eg
intramuscular
inject
transfect
keratinocyt
myocyt
express
transgen
releas
deriv
peptideprotein
via
exosom
apoptot
bodi
materi
endocytos
immatur
dendrit
cell
idc
subsequ
present
antigen
preferenti
via
major
histocompat
class
mhcii
cell
drain
lymph
node
direct
transfect
apc
includ
idc
result
endogen
transgen
express
henc
parallel
present
via
mhci
mhcii
yield
cell
respons
parallel
besid
cellular
immun
respons
humor
immun
respons
induc
b
cell
receptor
recogn
protein
antigen
acquir
help
preactiv
antigenspecif
cell
apc
transfect
directli
dna
vaccin
case
encod
antigen
express
process
antigenderiv
peptid
load
parallel
onto
mhci
mhcii
molecul
case
concomit
activ
antigenpres
apc
migrat
drain
lymph
node
prime
helper
cell
case
cutan
applic
transfect
keratinocyt
may
gener
antigen
releas
exosom
apoptot
bodi
intern
apc
gener
antigen
exogen
origin
load
rather
exclus
mhcii
result
activ
helper
cell
turn
contribut
b
cell
prime
yield
humor
immun
respons
requir
full
activ
cell
far
subpopul
dendrit
cell
dc
socal
cross
prime
potenti
abl
load
mhci
intern
antigen
intramuscular
applic
transfect
myocyt
may
undergo
apoptosi
apoptot
bodi
engulf
apc
exogen
antigen
crosspres
mhci
result
cell
respons
earli
studi
dna
vaccin
demonstr
prime
cytotox
lymphocyt
ctl
mostli
depend
bone
marrowderiv
dc
rather
induc
tissu
specif
cell
strictli
depend
cell
help
seriou
challeng
dna
vaccin
intend
induc
antitumor
immun
respons
caus
immun
evas
strategi
tumor
regard
tumor
cell
often
character
defect
process
antigen
subsequ
present
via
mhci
impair
express
mhci
addit
within
tumor
microenviron
parenchym
infiltr
immun
cell
may
overexpress
tolerancepromot
nonclass
mhci
molecul
like
human
leukocyt
antigen
hlag
hlae
besid
tumorassoci
macrophag
tam
protect
tumor
immun
respons
variou
mechan
includ
releas
antiinflammatori
express
surfac
receptor
like
program
deathligand
inhibit
function
activ
cell
effect
dna
vaccin
also
diminish
regulatori
cell
treg
promot
cancer
growth
inhibit
effector
cell
moreov
tamand
tumorderiv
mediat
promot
expans
myeloidderiv
suppressor
cell
mdsc
interfer
activ
cell
tumor
microenviron
attenu
effector
cell
well
use
dna
vaccin
earli
rais
safeti
concern
mainli
concern
probabl
stabl
integr
transfect
dna
genom
somat
even
germ
cell
caus
dysregul
gene
express
mutat
regard
wolff
collegu
demonstr
luciferaseencod
vector
intramuscular
administr
detect
month
skelet
muscl
extrachromosom
plasmid
howev
wang
cowork
report
intramuscular
inject
follow
elecotropor
strongli
enhanc
overal
transfect
rate
associ
low
level
chromosom
integr
vector
dna
random
site
howev
author
calcul
integr
frequenc
well
number
spontan
gene
mutat
subsequ
studi
major
plasmid
dna
administ
skelet
muscl
differ
rodent
found
remain
inject
site
minor
fraction
also
detect
organ
includ
gonad
integr
genom
concern
unwant
dna
vaccinationassoci
immun
effect
repeat
intramuscular
applic
luciferaseencod
report
vector
primat
result
long
term
report
express
induc
antidna
antibodi
potenti
transfer
prokaryot
element
dna
vaccin
like
antibiot
resist
gene
eg
gut
microbiom
consid
anoth
issu
safeti
concern
far
event
document
nonetheless
aforement
well
addit
safeti
concern
dna
vaccin
need
consid
regard
translat
use
clinic
present
approv
dna
vaccin
use
human
nevertheless
dnabas
vaccin
approv
fda
usda
veterinari
use
includ
vaccin
west
nile
viru
hors
canin
melanoma
one
first
human
clinic
trial
dna
vaccin
evalu
therapeut
prophylact
effect
hiv
signific
immun
respons
potenti
immunogen
detect
howev
year
wang
colleagu
demonstr
induct
cell
respons
primat
immun
mixtur
plasmid
encod
differ
plasmodium
falciparum
protein
anoth
clinic
trial
target
hepat
b
viru
show
induct
humor
respons
patient
respond
convent
vaccin
overal
safeti
dna
vaccin
thoroughli
proven
sever
clinic
trial
underlin
fact
antibodi
respons
prokaryot
part
dna
vaccin
observ
advers
effect
limit
mild
local
reactiv
inject
site
one
first
clinic
trial
employ
dna
vaccin
tumor
therapi
conduct
use
prostat
membran
antigen
prostat
cancer
antigen
deliv
use
adenovir
vector
granulocytemacrophag
colonystimul
factor
adjuv
trial
delayedtyp
hypersensit
respons
observ
therefor
subsequ
trial
pursu
goal
improv
paramet
vaccin
melanoma
patient
bival
dna
encod
melana
tyrosinas
tumorassoci
antigen
elicit
humor
ctl
respons
stage
iv
patient
subsequ
clinic
trial
use
synchrovax
vaccin
encod
four
peptid
epitop
melana
melanoma
antigen
recogn
cell
induc
broad
antigenspecif
cell
respons
trial
show
antigenspecif
respons
induct
tumor
regress
patient
recent
clinic
trial
show
good
result
induc
immun
respons
wilm
tumor
antigen
use
dna
vaccin
encod
two
differ
cell
epitop
altogeth
clinic
trial
employ
dna
vaccin
evok
effici
induct
cellular
humor
respons
howev
level
respons
often
suffici
elicit
signific
clinic
benefit
therefor
numer
clinic
trial
focu
dna
vaccin
optim
strategi
augment
theirimmunogen
present
follow
addit
necessari
compar
suitabl
differ
dna
vaccin
deliveri
rout
yield
potent
adapt
immun
respons
regard
cutan
mucos
hiv
vaccin
cuthivac
trial
worth
mention
sinc
aim
compar
analyz
influenc
combin
differ
inject
site
without
electropor
follow
optim
strategi
design
dna
vaccin
approach
improv
deliveri
apc
present
aspect
import
overcom
poor
immunogen
dna
vaccin
human
dna
vaccin
still
face
mani
challeng
becom
effect
tool
success
achiev
preclin
studi
translat
clinic
yet
biggest
challeng
low
immunogen
dna
vaccin
bigger
anim
human
probabl
due
difficulti
upscal
dna
vaccin
amount
use
small
anim
system
mg
dna
would
inject
averages
human
nake
ie
unformul
plasmid
dna
use
vaccin
import
factor
contribut
low
therapeut
effici
dna
degrad
studi
show
plasmid
compar
administr
form
like
minicircl
degrad
rel
fast
within
one
week
dna
molecul
success
enter
cell
need
pass
barrier
nuclear
membran
transcrib
henc
due
low
amount
dna
dispos
transfect
given
target
cell
vivo
major
goal
optim
transfect
optim
paramet
dna
vaccin
design
summar
figur
peptid
epitop
melana
melanoma
antigen
recogn
cell
induc
broad
antigenspecif
cell
respons
trial
show
antigenspecif
respons
induct
tumor
regress
patient
recent
clinic
trial
show
good
result
induc
immun
respons
wilm
tumor
antigen
use
dna
vaccin
encod
two
differ
cell
epitop
altogeth
clinic
trial
employ
dna
vaccin
evok
effici
induct
cellular
humor
respons
howev
level
respons
often
suffici
elicit
signific
clinic
benefit
therefor
numer
clinic
trial
focu
dna
vaccin
optim
strategi
augment
theirimmunogen
present
follow
addit
necessari
compar
suitabl
differ
dna
vaccin
deliveri
rout
yield
potent
adapt
immun
respons
regard
cutan
mucos
hiv
vaccin
cuthivac
trial
worth
mention
sinc
aim
compar
analyz
influenc
combin
differ
inject
site
without
electropor
follow
optim
strategi
design
dna
vaccin
approach
improv
deliveri
apc
present
aspect
import
overcom
poor
immunogen
dna
vaccin
human
dna
vaccin
still
face
mani
challeng
becom
effect
tool
success
achiev
preclin
studi
translat
clinic
yet
biggest
challeng
low
immunogen
dna
vaccin
bigger
anim
human
probabl
due
difficulti
upscal
dna
vaccin
amount
use
small
anim
system
mg
dna
would
inject
averages
human
nake
ie
unformul
plasmid
dna
use
vaccin
import
factor
contribut
low
therapeut
effici
dna
degrad
studi
show
plasmid
compar
administr
form
like
minicircl
degrad
rel
fast
within
one
week
dna
molecul
success
enter
cell
need
pass
barrier
nuclear
membran
transcrib
henc
due
low
amount
dna
dispos
transfect
given
target
cell
vivo
major
goal
optim
transfect
optim
paramet
dna
vaccin
design
summar
figur
optim
paramet
dna
vaccin
design
use
hybrid
viraleukaryot
promot
shown
prevent
transcript
silenc
observ
viral
promotor
altern
promot
engin
transcriptin
target
apc
like
dc
may
use
enhanc
antigen
express
especi
case
pathogen
codon
optim
import
induc
broad
cell
respons
linkersepar
sequenc
encod
differ
antigen
may
use
addit
fusion
sequenc
encod
invari
chain
may
enhanc
load
antigen
onto
mhcii
convent
molecular
adjuv
intend
enhanc
apc
activ
state
andor
cell
attract
polar
encod
express
vector
coadminist
dna
vaccin
ensur
coexpress
antigen
molecular
adjuv
transfect
cell
sequenc
must
incorpor
dna
vaccin
ci
separ
ire
sequenc
vector
backbon
compris
part
dna
vaccin
requir
eukaryot
express
inher
insert
immunostimulatori
sequenc
detect
danger
receptor
mediat
apc
activ
inclus
nl
facilit
nuclear
entri
dna
intrins
inhibitori
effect
backbon
transfect
effici
limit
insert
atrich
sequenc
recombinasemedi
delet
prokaryot
part
last
step
propag
bacteria
yield
minicircl
dna
convent
viral
promot
like
human
immediateearli
cmv
cytomegaloviru
promot
ubiquit
activ
high
level
employ
drive
transgen
express
howev
especi
regard
long
term
express
viral
promotor
often
subject
methylationmedi
inactiv
wherea
eukaryot
promot
hybrid
eukaryoticvir
promot
remain
activ
furthermor
use
cell
typespecif
promotor
may
allow
restrict
antigen
express
apc
achiev
transcript
target
dc
activ
state
constitut
potent
apc
popul
variou
promot
endogen
gene
express
predominantli
apc
popul
test
drive
dcfocus
transgen
express
well
establish
dcspecif
marker
mous
wherea
integrin
express
broadli
human
differ
immun
cell
type
transgen
mice
engin
express
antigen
transcript
control
larg
kb
promot
fragment
show
dcspecif
transgen
express
howev
mice
biolist
transfect
dna
vaccin
contain
promot
fragment
insuffici
ctl
activ
observ
dendrocyt
express
seven
transmembran
protein
dcstamp
constitut
evolutionarili
highli
conserv
transmembran
protein
endoplasm
reticulum
studi
dcstamp
report
primarili
express
immatur
human
mous
dc
downregul
respons
matur
howev
osteoclast
macrophag
report
express
dcstamp
well
suitabl
dcstamp
promotor
transcript
target
dc
evalu
transduct
hematopoiet
stem
cell
lentivir
express
vector
harbor
dcstamp
promot
drive
express
fluoresc
report
lethal
irradi
mice
reconstitut
transduct
report
express
monitor
differ
immun
cell
type
inde
report
primarili
express
differenti
convent
plasmacytoid
dc
low
level
monocyt
b
cell
nk
cell
ctype
lectin
receptor
clr
bind
mannoserich
surfac
structur
variou
pathogen
primarili
express
langerhan
cell
lc
constitut
epiderm
dc
popul
line
biolist
transfect
mice
report
plasmid
drive
luciferas
express
promot
yield
predomin
report
express
lc
subsequ
studi
transduct
mice
lentivir
report
express
vector
control
promotor
result
report
express
lc
well
macrophag
compar
studi
includ
aforement
gene
promot
promot
fragment
dendrit
cellspecif
intercellular
adhes
nonintegrin
dcsign
gene
encod
clr
predominantli
express
dc
macrophag
dcstamp
promot
identifi
potent
induc
antigenspecif
cell
respons
vitro
transfect
dc
highli
conserv
actinbundl
protein
highli
express
neuron
cell
mediat
structur
integr
axon
shown
besid
neuron
cell
express
activ
dc
mous
human
promot
yield
strong
specif
activ
dc
speci
subsequ
studi
demonstr
transcript
target
dc
use
dna
vaccin
contain
promot
drive
antigen
express
yield
antigenspecif
helper
cell
th
immun
respons
wherea
transfect
cmv
promoterdriven
dna
vaccin
result
mix
respons
moreov
cmv
promotor
contain
dna
vaccin
induc
ctl
compar
extent
variou
mous
model
allergeninduc
airway
inflamm
type
allergi
well
mous
model
multipl
sclerosi
vaccin
plasmid
encod
relev
allergenantigen
control
promot
show
therapeut
efficaci
especi
cotransfect
express
construct
encod
antiinflammatori
cytokin
transcript
target
dc
intend
restrict
antigen
adjuv
express
apc
popul
therebi
prevent
address
toler
regulatori
cell
type
like
mdsc
tam
howev
transcript
target
dc
also
larg
exclud
express
protein
antigen
b
cell
therebi
may
impair
induct
antigenspecif
antibodi
addit
b
cell
address
may
achiev
employ
cellular
promot
display
activ
also
apc
popul
use
dna
vaccin
infecti
diseas
tumor
therapi
enabl
focu
sequenc
encod
immunogen
peptid
given
pathogen
tumorspecif
protein
allow
includ
antigenencod
sequenc
deriv
differ
protein
within
one
minigen
induc
broader
cell
respons
antigen
express
tumor
cell
call
tumorassoci
antigen
taa
divid
two
categori
tumorspecif
share
antigen
tumorspecif
uniqu
antigen
share
antigen
express
differ
tumor
also
present
normal
cell
differ
tissu
although
lower
amount
tumorspecif
uniqu
antigen
ie
neoantigen
express
individu
tumor
usag
share
antigen
conveni
sinc
sequenc
protein
well
known
genet
analysi
mutanom
need
select
antigenencod
sequenc
howev
major
risk
use
share
taa
induct
autoimmun
respons
immun
system
also
turn
healthi
tissu
express
antigen
neoantigen
seem
first
choic
design
dna
vaccin
studi
shown
effector
cell
respons
potent
mutat
antigen
furthermor
antigen
higher
halflif
shown
induc
stronger
cytotox
cell
respons
therebi
increas
immunogen
codon
optim
mostli
need
target
antigen
nonhuman
origin
strongli
enhanc
antigen
express
besid
immunogen
peptid
antigen
known
induct
antibodi
specif
target
protein
issu
sequenc
encod
relev
cell
antigen
epitop
may
includ
even
encod
antigen
express
high
amount
antigen
presentationrecognit
still
may
obstacl
prompt
suffici
immun
respons
problem
address
introduc
epitopespecif
chang
antigen
increas
mhc
affin
similar
effort
made
increas
affin
mhcpeptid
complex
cell
receptor
latest
approach
increas
antigen
present
use
xenogen
antigen
approach
success
develop
usdaapprov
dna
vaccin
canin
melanoma
current
studi
strategi
administ
dna
vaccin
encod
full
length
protein
sourc
antigen
administr
dna
vaccin
encod
differ
peptid
antigen
follow
former
approach
aim
induc
cellular
concomit
humor
immun
respons
latter
focus
induct
cell
respons
expens
antibodi
product
design
antigenencod
express
unit
includ
select
sever
immunogen
antigen
deriv
one
differ
protein
present
via
mhciii
yield
parallel
cell
activ
conceiv
codon
optim
eventu
strategi
boost
mhcii
antigen
present
eg
introduc
invari
chain
avoid
induct
vaccinemedi
antigenspecif
toler
apc
need
activ
socal
danger
signal
promot
upregul
antigen
present
receptor
costimul
proinflammatori
mediat
effici
cell
activ
polar
end
antigenencod
vaccin
coadminist
establish
adjuv
like
aluminium
saltbas
alum
immunostimulatori
cpg
oligonucleotid
engag
endosom
locat
tolllik
receptor
tlr
stimul
apc
intraderm
applic
plasmid
observ
yield
immun
respons
due
cpgrich
element
locat
within
ampicillin
resist
gene
besid
cytosol
dna
sensor
mediat
activ
stimul
interferon
gene
signal
pathway
contribut
intrins
adjuv
effect
dna
vaccin
apart
intrins
adjuv
plasmid
dna
codeliveri
plasmid
encod
transcript
factor
genet
adjuv
test
stimul
apc
upregul
activ
transcript
factor
nuclear
factor
kappalightchainenhanc
activ
bcell
interferonregulatori
factor
irf
famili
hallmark
apc
stimul
danger
signal
shedlock
cowork
demonstr
codeliveri
hiv
protein
encod
dna
vaccin
express
construct
vivo
electropor
mice
elev
cellular
humor
immun
respons
codeliveri
influenza
antigen
encod
dna
vaccin
encod
vector
biolist
transfect
mice
result
increas
activ
cell
cotransfect
express
vector
yield
enhanc
viral
antigenspecif
antibodi
product
wherea
enhanc
express
increas
cell
b
cell
respons
howev
combin
hiv
tat
antigen
dna
vaccin
deliv
intramuscular
inject
codeliveri
encod
vector
elev
intend
respons
achiev
coactiv
irf
transcript
factor
luc
cowork
immun
mice
influenza
protein
encod
dna
vaccin
plasmid
encod
virusinduc
signal
adaptor
protein
result
elev
antivir
cell
respons
compar
studi
larsen
colleagu
assess
abil
codeliv
express
vector
numer
differ
tlr
signal
adaptor
enhanc
immun
respons
seventeen
differ
signal
adaptor
test
combin
coadministr
tram
express
vector
enhanc
clt
respons
vivo
aforement
strategi
aim
enhanc
activ
state
transfect
apc
approach
dna
vaccin
coadminist
plasmid
encod
either
costimulatori
receptor
transfect
apc
enhanc
cell
stimulatori
capac
report
use
eg
de
colleagu
evok
potent
antivisnamaedi
viru
cell
antibodi
respons
immun
sheep
often
dna
vaccin
codeliv
express
construct
solubl
mediat
like
cytokin
chemokin
exert
stimulatorychemoattract
effect
apc
immun
cell
exampl
produc
activ
apc
promot
differenti
also
stimul
apc
accordingli
administr
express
construct
combin
multigen
hiv
dna
vaccin
intramuscular
electropor
result
enhanc
antigenspecif
activ
healthi
volunt
also
releas
activ
dc
exert
broad
stimulatori
effect
effector
cell
b
cell
nk
cell
well
dc
sever
studi
pronounc
effect
cotransfect
observ
report
eg
sun
cowork
demonstr
fusion
construct
mycobacterium
antigen
appli
intramuscularli
mice
yield
pronounc
nk
activ
enhanc
ctl
respons
well
elev
antibodi
titer
altogeth
differ
cytokin
employ
genet
adjuv
stimul
apc
type
immun
cell
act
mainli
cell
nk
cell
henc
overexpress
intend
support
sustain
activ
exhaust
effector
cell
overcom
deplet
treg
recent
altern
promot
apc
cell
activ
express
intracellular
secret
factor
concept
regul
cell
activ
rna
interfer
gain
attent
either
specif
silenc
rna
plasmid
encod
short
hairpin
rna
specif
target
intracellular
mrna
encod
inhibitori
factor
appli
approach
transcript
factor
like
signal
transduc
activ
transcript
known
induc
express
protolerogen
factor
downstream
target
like
coinhibitori
surfac
receptor
counteract
apcmedi
costimul
target
furthermor
microrna
mirna
speci
regul
activ
state
apc
recogn
interest
target
exampl
deliveri
plasmid
harbor
multipl
mirna
consensu
bind
site
term
mirna
spong
intend
limit
inhibitori
effect
activationassoci
mrna
target
current
human
dna
vaccin
approach
antigenencod
dna
vaccin
coadminist
solubl
immunostimulatori
agent
often
approv
antitumor
adjuv
therapi
besid
express
vector
encod
cytokin
chemokin
clinic
test
far
dna
vaccin
integr
antigen
express
unit
molecular
adjuv
singl
plasmid
test
limit
number
studi
transfect
prokaryot
part
dna
vaccin
necessari
earli
studi
shown
overal
size
dna
vaccin
invers
correl
transfect
effici
even
mitot
activ
cell
line
effect
attribut
least
part
silenc
transgen
express
consequ
heterochromatin
format
bacteri
compon
spread
promotervaccin
express
cassett
circumv
problem
concept
delet
prokaryot
sequenc
plasmid
propag
bacteria
develop
yield
socal
minicircl
dna
recent
lu
colleagu
report
inclus
atrich
sequenc
vector
backbon
prevent
transcript
silenc
howev
grow
number
studi
increas
efficaci
minicircl
dna
vaccin
compar
convent
plasmid
demonstr
concern
combin
administr
dna
vaccin
genet
adjuv
see
bicistron
vector
avail
enabl
express
gene
ci
vector
contain
either
two
differ
promot
independ
express
transgen
express
unit
separ
sequenc
like
intern
ribosom
entri
site
ire
mediat
capindepend
translat
downstream
express
unit
especi
due
frequent
observ
strongli
differ
express
intens
transgen
altern
virusderiv
sequenc
introduc
instead
translat
peptid
sequenc
recogn
endogen
proteas
mediat
posttransl
cleavag
differ
transgen
usag
ire
sequenc
interest
use
cell
typespecif
promot
transcript
target
apc
effici
transfer
dna
vaccin
cell
nucleu
subsequ
express
import
obstacl
success
transfect
especi
case
mitot
inact
cell
like
apc
quit
earli
certain
dna
sequenc
identifi
mediat
nuclear
transloc
one
first
identifi
simian
viru
sv
enhanc
region
transcript
factor
bind
site
cytoplasm
facilit
activ
nuclear
entri
plasmid
dna
due
nuclear
local
signal
nl
consequ
approach
enhanc
site
includ
vector
backbon
altern
nl
activ
virusderiv
peptid
like
larg
tantigen
exploit
facilit
nuclear
plasmid
transloc
attach
peptid
either
directli
vector
backbon
dna
deliveri
system
nanocarri
nc
offer
advantag
shield
dna
vaccin
degrad
dnase
enzym
surfac
modif
nc
moieti
like
antibodi
natur
ligand
like
carbohydr
may
enabl
direct
target
dc
outlin
direct
transfect
apc
would
prevent
unwant
uptak
antigen
adjuv
mdsc
tam
promot
tumor
toler
addit
intern
express
transgen
ensur
suffici
amount
antigen
present
via
mhci
yield
robust
cell
respons
nc
defin
particl
nm
size
interfaci
layer
compos
differ
materi
gain
scientif
interest
due
uniqu
properti
wide
rang
applic
link
varianc
composit
size
shape
surfac
modif
far
nc
use
predominantli
deliveri
system
drug
adjuv
nucleic
acidbas
vaccin
contribut
emerg
field
nanovaccin
one
frequent
applic
nc
use
tumor
therapi
mani
advantag
classic
chemotherapeut
pharmacolog
agent
like
improv
bioavail
organ
cell
type
specif
target
tunabl
drug
releas
address
organel
exact
mode
interact
nc
cell
membran
strongli
influenc
size
charg
shape
hydrophilichydrophob
surfac
properti
former
uptak
often
occur
either
membran
penetr
associ
transient
appear
hole
receptormedi
endocytosi
cellular
uptak
endosom
releas
nccomplex
dna
enhanc
cell
penetr
peptid
cpp
either
attach
directli
dna
dnacomplex
nc
howev
studi
perform
serumpoor
condit
vitro
possibl
rapid
format
protein
corona
around
nc
engag
neg
charg
serum
compon
cpp
prior
cellular
engag
need
taken
account
nc
surfac
modif
like
dens
decor
polyethylen
glycol
peg
introduc
limit
serum
protein
adsorpt
retain
cpp
activ
major
safeti
concern
associ
use
nc
biocompat
biodistributiion
clearanc
induct
unwant
immun
reaction
exampl
repetit
applic
pegcoat
nc
may
result
aris
pegspecif
antibodi
develop
new
ncbase
deliveri
system
stir
hope
field
gene
therapi
cancer
treatment
apc
assign
recogn
pathogen
particl
similar
size
pathogen
easili
engulf
dc
normal
ingest
particl
viruslik
size
nm
macrophag
usual
engulf
larger
particl
nc
efficaci
uptak
apc
strongli
depend
surfac
properti
shape
nc
cation
particl
intern
better
apc
also
like
induc
platelet
aggreg
hemolysi
also
shape
particl
crucial
uptak
gold
np
aunp
demonstr
spheric
particl
effici
shape
addit
hydrophob
surfac
modif
deliv
cargo
influenc
interact
immun
cell
need
consid
factor
also
influenc
interact
serum
protein
ie
modif
unpredict
effect
organ
outlin
field
nanomateri
still
emerg
result
new
design
open
new
opportun
use
like
develop
viruslik
particl
vlp
magnet
particl
may
direct
vivo
appli
magnet
field
introduct
tumor
microenvironmenttrigg
drug
releas
mechan
still
mani
challeng
link
use
nc
includ
issu
whether
activ
target
specif
cell
tissu
possibl
need
therapeut
efficaci
ncmediat
deliveri
nucleic
acidbas
therapeut
promis
approach
sever
extraand
intracellular
barrier
still
limit
transfect
efficaci
henc
nc
intend
deliveri
nucleic
acidbas
therapeut
need
fulfil
number
requir
deliveri
vector
offer
suffici
capac
effici
packag
dnarna
per
se
obstacl
especi
longer
plasmid
dna
order
enabl
deliveri
suffici
amount
molecul
per
target
cell
ii
deliveri
system
show
stabil
serum
protein
may
form
protein
corona
around
nc
therebi
affect
target
uptak
effici
iii
uptak
cell
nc
cargo
evad
endolysosom
degrad
enter
cytoplasm
endosom
escap
releas
mrna
translat
directli
cytoplasm
dna
vaccin
need
transloc
nucleu
subsequ
transcript
may
enhanc
nl
numer
differ
type
nc
regard
materi
size
shape
advantag
disadvantag
field
nanomedicin
inorgan
nanomateri
rigid
structur
control
synthesi
allow
simpl
modif
aunp
show
low
cytotox
effect
biocompat
use
carrier
virusderiv
antigen
well
dna
vaccin
sinc
plasmid
dna
complex
directli
surfac
particl
addit
proteinco
aunp
report
possess
intrins
immunostimulatori
capac
mediat
dc
activ
transfect
effici
increas
use
cpp
coat
aunp
thu
minim
influenc
cell
environ
plasmid
dna
facilit
cell
uptak
anoth
interest
candid
nucleic
acid
deliveri
silicabas
nc
biocompat
deliv
differ
type
cargo
note
nc
demonstr
passiv
target
tumor
tissu
mesopor
silica
nc
use
dna
transfect
cell
line
vitro
gener
nc
allow
control
releas
cargo
modif
pore
size
shape
well
surfac
function
graphen
oxid
compound
consist
mainli
carbon
oxygen
layer
structur
electrostat
interact
show
high
load
capac
well
control
releas
cargo
addit
graphen
oxid
protect
nucleic
acid
cleavag
make
remark
candid
gene
therapi
neg
charg
carbon
nc
direct
transfer
dna
via
cell
membran
cytosol
demonstr
anoth
type
carbonbas
nanomateri
suitabl
transfer
nucleic
acid
carbon
nanotub
cnt
cnt
small
chemic
inert
howev
hydrophob
limit
use
biomed
applic
cnt
poorli
solubl
water
improv
biocompat
cnt
modifi
coval
often
reduc
load
capac
nucleic
acid
well
intracellular
releas
cargo
magnet
particl
like
iron
oxid
core
particl
uniqu
abil
provid
cargo
deliveri
also
allow
detect
vivo
magnet
reson
imag
approach
test
clinic
cancer
therapi
target
magnet
particl
tumor
tissu
induc
magnet
hyperthermia
improv
biocompat
magnet
particl
often
coat
protein
polym
polysaccharid
reduc
cytotox
effect
improv
dna
transfect
properti
lipid
also
use
gene
deliveri
felgner
colleagu
first
demonstr
n
propyl
n
n
ntrimethylammonium
chlorid
dotap
transfer
dna
cell
complex
compos
dotap
protaminecondens
dna
show
good
transfect
effici
vivo
cation
lipid
gener
suitabl
transfect
prefer
interact
anion
cell
membran
thu
facilit
uptak
transfect
complex
cell
chargedriven
interact
cellular
receptor
initi
endocytosi
shown
uptak
mechan
cation
liposom
furthermor
cation
lipid
show
great
bind
dna
form
liposom
protect
cargo
degrad
posit
effect
achiev
addit
neutral
helper
lipid
stabil
lipidbilay
may
promot
endosom
escap
passeng
dna
either
due
ph
buffer
protonat
group
fusion
endosom
membran
case
cation
dotapbas
liposom
contain
cholesterol
helper
lipid
macropinocytos
identifi
major
uptak
mechan
recent
incorpor
coiledcoil
lipopeptid
liposom
bilay
demonstr
promot
interact
cell
membran
receptor
direct
releas
cargo
cytosol
liposom
also
encapsul
protein
antigen
commonli
use
adjuv
deliveri
system
spontan
rearrang
nanostructur
sever
liposom
proteinbas
substanc
approv
decad
ago
prophylact
vaccin
herp
simplex
viru
influenza
protein
constitut
favor
materi
nc
gener
sinc
biocompat
biodegrad
typic
show
low
cytotox
good
choic
gene
deliveri
system
gelatin
b
combin
protamin
sulfat
overal
neg
charg
protein
switch
endosom
lead
releas
cargo
major
drawback
system
rel
low
dna
load
capac
endogen
protein
also
use
design
nc
gene
deliveri
good
exampl
albumin
gener
larg
liver
constitut
abund
serum
protein
albumin
demonstr
exert
sever
task
via
transient
bind
extracellular
compon
includ
protect
protein
fatti
acid
peroxid
modif
ion
transport
adsorpt
drug
affect
bioavail
line
albumin
mani
reactiv
group
surfac
allow
chemic
modif
nc
consist
albumin
core
chitosan
outer
layer
success
transfect
differ
cell
line
surfacemodifi
ethylenediamin
introduct
cation
properti
serv
deliv
sirna
metastat
tumor
vivo
vlp
consist
variou
selfassembl
viral
protein
may
constitut
suitabl
candid
gene
deliveri
combin
abil
viru
interact
immun
cell
lack
infecti
properti
howev
vpl
protein
demonstr
serv
antigen
due
exogen
origin
constitut
unwant
side
effect
anyway
first
vlpbase
vaccin
commerci
sever
antivir
one
malariadirect
vaccin
clinic
use
often
combin
classic
adjuv
alum
polymerbas
nanomateri
gain
interest
electrostat
interact
nucleic
acid
result
protect
enzymat
degrad
furthermor
cation
polymer
nanomateri
cheap
nonimmunogen
safe
greater
dnaload
capac
virus
first
polymer
particl
report
enhanc
transfect
diethylaminodextran
late
polymer
system
often
surfacemodifi
prolong
circul
time
bloodstream
enabl
specif
even
celltarget
deliveri
one
option
shield
nc
format
protein
corona
determin
cellular
interact
use
peg
cation
polylactid
exampl
problem
shown
pegyl
particl
perform
better
serum
high
polymerdna
ratio
commerci
avail
transfect
reagent
import
polymerbas
materi
emphas
earli
demonstr
cation
polym
bind
dna
also
effect
condens
form
structur
resembl
virus
among
best
studi
polymer
nanomateri
polyd
llactidecoglycolid
plg
polyd
llacticcoglycol
acid
plga
plgand
plgabas
particl
biocompat
biodegrad
show
sustain
releas
wide
rang
differ
cargo
molecul
includ
dna
polyllysin
pll
natur
polym
peptid
structur
therefor
highli
biodegrad
howev
transfect
effici
pll
particl
lower
obtain
use
polyethylenimin
pei
polymer
structur
achiev
mileston
first
receptor
target
transfect
perform
asialoglycoprotein
introduc
pll
target
receptor
result
increas
transfect
vivo
improv
transfect
effici
polymer
system
equip
target
moieti
earli
approach
inactiv
adeno
rhino
virus
use
combin
receptor
target
polyplex
enhanc
endosom
escap
system
protein
often
use
regard
sulfhydrylactivat
listeriolysin
oprotamin
conjug
show
enhanc
deliveri
dna
cytosol
altern
polyamidoamin
dendrim
shown
exert
promin
proton
spong
effect
amin
slightli
proton
neutral
ph
pei
report
yield
better
transfect
capac
linear
compar
branch
polym
suggest
unpack
dna
complic
complex
latter
howev
pei
biodegrad
show
high
toxic
effect
molecular
weightdepend
manner
addit
cation
polym
gener
recogn
immun
system
shown
trigger
complement
activ
lead
untim
clearanc
nc
approach
suitabl
natur
polym
gener
nc
demonstr
exampl
chitosan
shown
constitut
suitabl
dna
carrier
bear
intrins
adjuv
activ
similar
polysaccharidebas
polym
like
inulin
other
transfect
mani
apc
possibl
target
dna
vaccin
deliveri
secondari
lymphoid
organ
via
system
applic
like
intraven
inject
oral
pulmonari
administr
suitabl
strategi
altern
dna
vaccin
often
appli
often
topic
via
skin
intramuscularli
figur
present
overview
common
dna
vaccin
rout
similarli
vaccin
studi
transfect
rate
myocyt
intramuscular
inject
dna
intend
gener
antigen
uptak
apc
found
strongli
elev
electropor
well
gener
electropor
context
transderm
intramuscular
dna
vaccin
report
result
local
activ
innat
immun
may
consequ
eg
electroporationinduc
cellular
stress
reaction
includ
necrosi
figur
rout
dna
vaccin
delikveri
dna
vaccin
may
deliv
system
intraven
inject
reach
secondari
lymphat
organ
oral
applic
attenu
bacteria
vehicl
confer
uptak
dna
intestin
apc
pulmonari
administr
nebul
dna
achiv
uptak
lung
cell
transderm
deliveri
primarili
adress
lc
needlefre
deliveri
particleadsorb
dna
vaccin
helium
pressur
gene
gun
pmed
needlebas
administr
via
microneedl
tattoo
devic
clinic
test
transfect
cutan
apc
well
nonapc
intraderm
inject
dna
vaccin
enhanc
immedi
electropor
subcutan
inject
mainli
result
transfect
fibroblast
keratinocyt
express
transgen
releas
antigen
uptak
apc
likewis
intramuscular
inject
dna
vaccin
primarili
yield
transfect
myocyt
expressreleas
antigen
apc
uptak
myocyt
transfect
rate
enhanc
electroport
site
inject
well
concern
success
immun
differ
dna
vaccin
rout
recent
phase
trial
cuthivec
assess
compar
manner
efficaci
differ
dna
vaccin
administr
rout
show
increas
antigen
specif
respons
combin
figur
rout
dna
vaccin
delikveri
dna
vaccin
may
deliv
system
intraven
inject
reach
secondari
lymphat
organ
oral
applic
attenu
bacteria
vehicl
confer
uptak
dna
intestin
apc
pulmonari
administr
nebul
dna
achiv
uptak
lung
cell
transderm
deliveri
primarili
adress
lc
needlefre
deliveri
particleadsorb
dna
vaccin
helium
pressur
gene
gun
pmed
needlebas
administr
via
microneedl
tattoo
devic
clinic
test
transfect
cutan
apc
well
nonapc
intraderm
inject
dna
vaccin
enhanc
immedi
electropor
subcutan
inject
mainli
result
transfect
fibroblast
keratinocyt
express
transgen
releas
antigen
uptak
apc
likewis
intramuscular
inject
dna
vaccin
primarili
yield
transfect
myocyt
expressreleas
antigen
apc
uptak
myocyt
transfect
rate
enhanc
electroport
site
inject
well
intraven
applic
dna
vaccin
inprincipl
allow
reach
apc
locat
secodnari
lymphoid
organ
howev
physicochem
characterist
dnacomplex
nc
determin
biodistribut
dna
vaccin
exampl
peicomplex
report
express
vector
preferenti
transfect
lung
cell
wherea
lipsomom
formul
transfect
liver
cell
gener
numer
type
nc
demonstr
interact
blood
compon
therebi
form
protein
corona
around
nc
turn
may
strongli
affect
cellular
bind
properti
exampl
recent
shown
nc
coat
wtih
dextran
confer
biocompat
trigger
lectindepend
pathway
complement
activ
result
deposit
fragment
nc
surfac
preferenti
bind
splenic
b
cell
via
complement
receptor
oral
administr
dna
nonpathogen
l
lacti
attenu
thyphimurium
l
monocytogen
bacteri
strain
often
use
vector
term
bactofect
intestin
bacteria
may
phagocytos
directli
mucos
dcmacrophag
spread
extens
gut
lumen
cellmedi
transcytosi
peyer
patch
phagocytosi
plasmid
dna
releas
phagolysosom
numer
bacteriaassoci
danger
signal
result
profound
apc
activ
recent
bacteri
ghost
constitut
bacteri
envelop
introduc
carrier
dna
vaccin
asid
oral
applic
bacteria
shown
confer
transfect
apc
appli
mucos
site
eg
appli
intranas
recent
dna
vaccin
deliveri
properti
oral
appli
bacteria
exampl
regard
phagolysosom
escap
improv
addit
coat
nc
compar
sytem
rout
dna
vaccin
pulmonari
applic
aerol
dna
vaccin
rather
new
approach
usag
nake
nccomplex
dna
demonstr
yield
transfect
lung
epitheli
cell
henc
far
research
focuss
therapeut
treatment
local
gene
defect
case
cystic
fibrosi
skin
constitut
interest
target
organ
dna
vaccin
due
rather
high
frequenc
cutan
dc
exampl
human
skin
depend
specif
site
contain
lc
per
squar
millimet
furthermor
skin
activ
dc
cell
popul
show
migratori
behavior
toward
drain
lymph
node
evok
cell
respons
differ
transdermakl
dna
vaccin
strategi
develop
suitabl
clinic
test
needlefre
biolist
transfect
mediat
gene
gun
pmed
particlemedi
epiderm
deliveri
devic
transfer
microparticleadsorb
dna
epiderm
layer
helium
forc
transfect
lc
dermal
dc
keratinocyt
note
physic
stress
associ
biolist
transfect
report
suffici
mediat
activ
emigr
directli
transfect
dc
microneedl
produc
variou
materi
techniqu
display
lenght
one
micron
tattoo
devic
address
cell
type
well
convent
intraderm
administr
dna
vaccin
syring
aim
transfect
dermal
dc
fibroblast
base
observ
intraderm
inject
dna
short
electr
puls
term
electropor
mediat
severalfold
enhanc
transfect
result
develop
number
accord
devic
test
clinic
studi
similarli
vaccin
studi
transfect
rate
myocyt
intramuscular
inject
dna
intend
gener
antigen
uptak
apc
found
strongli
elev
electropor
well
gener
electropor
context
transderm
intramuscular
dna
vaccin
report
result
local
activ
innat
immun
may
consequ
eg
electroporationinduc
cellular
stress
reaction
includ
necrosi
concern
success
immun
differ
dna
vaccin
rout
recent
phase
trial
cuthivec
assess
compar
manner
efficaci
differ
dna
vaccin
administr
rout
show
increas
antigen
specif
respons
combin
intramuscular
transcutan
inject
compar
intramuscular
plu
intraderm
inject
former
approach
even
effici
intramuscular
administr
follow
electropor
ep
inject
side
ep
frequent
use
increas
overal
transfect
effici
inject
site
shown
effici
enhanc
immun
respons
rhesu
macaqu
dna
vaccin
gener
applic
method
beyond
mediat
apc
activ
may
also
influenc
cell
polar
compar
studi
intramuscular
dna
vaccin
result
cell
respons
see
wherea
biolist
transfect
yield
respons
regard
distribut
dna
vaccin
complex
nc
noteworthi
small
particl
easili
transport
lymph
node
larger
particl
remain
longer
site
administr
addit
rout
administr
also
account
fate
deliveri
system
subcutan
inject
small
pegyl
liposom
found
larger
amount
lymph
node
intraven
intraperiton
inject
concern
nc
clearanc
bodi
nc
smaller
nm
clear
renal
extent
renal
clearanc
shown
correl
extent
neg
charg
biliari
clearanc
observ
especi
particl
nm
strongli
charg
particl
convent
applic
rout
nake
nccomplex
dna
may
result
predominantli
transfect
nonapc
turn
may
gener
releas
antigen
may
engulf
apc
howev
dc
popul
crosspres
potenti
abl
shuttl
fraction
extracellular
antigen
toward
mhci
enabl
stimul
cell
therefor
pronounc
ctl
activ
requir
direct
transfect
apc
due
pathogenlik
appear
term
size
shape
nccomplex
dna
vaccin
may
passiv
target
apc
like
convent
dc
macrophag
sinc
cell
type
special
uptak
foreign
materi
usag
either
natur
ligand
antibodi
specif
endocyt
activ
receptor
strongli
express
apc
may
enabl
cell
typefocuss
target
moieti
may
coupl
nake
dna
dna
complex
nc
target
clr
predominantli
express
dc
macrophag
constitut
suitabl
candid
exampl
dcsign
mannos
receptor
express
either
cell
type
differenti
intens
respect
mediat
intern
mannosyl
particl
qiao
cowork
demonstr
vaccin
mice
mannosyl
cation
liposom
complex
hiv
proteinencod
plasmid
dna
result
improv
immun
respons
mice
intramuscular
applic
dna
vaccin
encod
botulinum
neurotoxin
fuse
singl
chain
antibodi
fragment
scfv
specif
clr
result
improv
cellular
humor
immun
respons
protect
vaccin
anim
botulinu
infect
fusion
tumor
antigen
encod
dna
vaccin
scfv
protect
mous
breast
cancer
model
slow
tumor
growth
therapeut
set
immunogen
dna
vaccin
human
ist
still
low
yield
therapeut
convinc
result
howev
last
year
differ
approach
shown
optim
differ
paramet
contribut
enhanc
transfect
henc
immunogen
dna
vaccin
also
human
henc
ideal
dna
vaccin
need
complex
apctarget
nc
prevent
extracellular
degrad
enabl
direct
apc
transfect
contain
nl
facilit
nuclear
entri
dna
vaccin
contain
promot
facilit
transcript
target
apc
prevent
unwant
antigen
express
tolerancepromot
cell
type
like
mdsc
furthermor
dna
vaccin
includ
genet
adjuv
promot
activ
transfect
apc
prevent
antigenspecif
toler
induct
note
sever
type
nc
bear
intrins
immunostimulatori
activ
mode
dna
deliveri
may
also
result
local
inflamm
factor
need
consid
sinc
contribut
shape
charact
induc
immun
respons
especi
regard
cell
polar
regard
tumor
therapi
recent
progress
cost
effect
deep
sequenc
allow
identifi
patientsspecif
tumor
antigen
administr
dna
vaccin
outlin
aim
induc
antigensspecif
immun
respons
addit
applic
agent
inhibit
immunoregulatori
myeloid
cell
like
mdsc
treg
well
tumor
may
synergist
effect
besid
chemotherapeut
checkpoint
inhibitor
recent
introduc
clinic
therapi
like
candid
cotreat
fund
dh
mb
fund
deutsch
forschungsgemeinschaft
project
author
declar
conflict
interest
